Mar 30, 2022 / 02:00PM GMT
Pablo Divasson del Fraile - Almirall, S.A. - Head of IR & Corporate External Communication
Thank you, Nadia. Good afternoon to everyone on the call. Thank you for joining us on this call to review the 16-week data from lebrikizumab Phase III study. As usual, you can find the slides to this call on the Investors page of our website at almirall.com.
Moving to Slide 2. I would like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. With that, please advance to Slide 3.
Presenting today, we have Gianfranco Nazzi, Chief Executive Officer; and Karl Ziegelbauer, Chief Scientific Officer. Gianfranco will start with a focus on the atopic dermatitis market. Karl will then provide you with detail on the atopic dermatitis, the IL-13 pathway and the 16-week Phase III of lebrikizumab. Gianfranco will then make the closing comments before opening up for a Q&A session.
I would like to pass you over to our CEO, Gianfranco Nazzi.
Almirall SA Lebrikizumab ADVocate 1 and 2 Call Transcript
Mar 30, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers